Quantum Cancer Drug Discovery

QSAM-powered molecular screening for precision oncology

Overview

13th Chamber’s Cancer Drug Discovery module uses quantum computing to analyze drug-target binding affinities with precision impossible for classical computers. By encoding molecular structures into quantum circuits via QSAM, we screen combinations of FDA-approved compounds against specific cancer types — identifying synergistic drug pairs that classical methods miss.

How It Works

Quantum Molecular Screening Pipeline

Binary Drug Data — Molecular structure, binding site geometry, and pharmacological properties are digitized into binary format
QSAM Qubit Encoding — Binary data is converted into quantum rotation angles (Ry, Rz gates) across 4-qubit circuits
Variational Circuit Optimization — Parameterized quantum circuits model drug-target interactions through quantum entanglement
SCORE Error Correction — 50x fidelity improvement ensures reliable results from NISQ hardware
Synergy Score Extraction — Quantum measurements yield interaction scores; values above 0.7 indicate recommended combinations

Database Coverage

59

FDA-approved compounds including Cisplatin, Doxorubicin, Paclitaxel, Methotrexate

29

Cancer types including lung, breast, colorectal, leukemia, melanoma

8

Drug combinations evaluated simultaneously per circuit execution

Key Results

12.4x Quantum Advantage

Quantum molecular screening achieves 12.4x speed advantage over classical drug screening methods for multi-compound interaction analysis.

0.87 Synergy Score

QSAM-encoded screening consistently identifies Cisplatin-based regimens with strong synergy with taxanes for solid tumors — validated against clinical literature.

Patient Simulator

Built-in patient simulator models specific genetic marker combinations, allowing researchers to test treatment protocols against individual patient profiles.

Technology

The quantum advantage comes from the ability to model multiple molecular interaction pathways simultaneously through qubit superposition. Where classical screening tests one drug combination at a time, QSAM encodes multiple compounds into entangled quantum states, evaluating their collective interaction profile in a single circuit execution.

ESCORT tunneling protocols add additional analysis capabilities, using entangled state coordination to model quantum tunneling effects in drug-target binding — effects that are invisible to classical simulation.

Get Access

Cancer Drug Discovery is included in Quantum Nexus v1.2.0. Download from our Downloads page or contact us for institutional licensing.

Download Quantum Nexus

Disclaimer: This module is a research tool. Independent results vary and are not guaranteed. Not intended for clinical decision-making without appropriate medical oversight.